Jan Hillson

Title: Jan Hillson: Innovator in ANCA-Associated Vasculitis Treatment

Introduction

Jan Hillson is a notable inventor based in Mountain View, CA (US). She has made significant contributions to the field of medicine, particularly in the treatment of ANCA-associated vasculitis. With a total of 2 patents, her work is paving the way for innovative therapeutic methods.

Latest Patents

Jan Hillson's latest patents focus on the dosing and effect of C5a antagonists in treating ANCA-associated vasculitis. The first patent provides methods for treating this condition in humans by administering a therapeutically effective amount of avacopan or a pharmaceutically acceptable salt thereof. This method ensures that the levels of plasma complement factors Bb, C3a, or C5a do not significantly change during treatment. The second patent reiterates these methods, emphasizing the importance of maintaining stable plasma levels while effectively treating patients.

Career Highlights

Jan Hillson is currently employed at Chemocentryx, Inc., where she continues to develop innovative treatments for complex medical conditions. Her expertise in pharmacology and therapeutic methods has positioned her as a key player in her field.

Collaborations

Jan collaborates with talented coworkers, including Jun Deng and Petrus Bekker, to advance research and development in their projects. Their combined efforts contribute to the success of their initiatives at Chemocentryx, Inc.

Conclusion

Jan Hillson's work in the treatment of ANCA-associated vasculitis showcases her dedication to medical innovation. Her patents reflect a commitment to improving patient outcomes through effective therapeutic methods.